Aminex Therapeutics Obtains $4,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2f14a20f-02e0-4b53-b890-2c1c815fd89f - Date
11/11/2015 - Company Name
Aminex Therapeutics - Mailing Address
11335 NE 122nd Way Kirkland, WA 98034 USA - Company Description
Aminex Therapeutics, Inc., is a drug development company focused on discovery, development, and commercialization of a new subclass of cancer immunotherapies known as suppressor cell modulators (SCMs). - Website
http://www.aminextx.com - Transaction Type
Venture Equity - Transaction Amount
$4,000,000 - Transaction Round
Series A - Proceeds Purposes
The proceeds will be used to finalize Aminex’s preclinical testing and prepare for Phase 1/2A human clinical trials to start midyear 2016. Our patented AMX-513 combination therapy enables the immune system to attack cancer by regulating myeloid-derived suppressor cells. - M&A Terms
- Venture Investor
Undisclosed
